Skip to content
    New Rhein Healthcare Investors logo

    New Rhein Healthcare Investors

    Philadelphia, Pennsylvania, United StatesFounded 2010

    New Rhein Healthcare Investors is a Philadelphia-based venture capital firm that applies a private equity investment approach to life sciences investing, focusing on later-stage, de-risked clinical assets in pharmaceuticals and medical devices.

    40% of their portfolio is in Healthcare. They made 1 investments in the last 12 months. Their most common stage is series-c (40% of deals). Average disclosed round size is $61.6M (across 5 rounds with reported amounts).

    Find people at New Rhein Healthcare Investors on Goldilocks AI

    Portfolio

    5

    Fund Size

    Top Stage

    Series C

    Last 12 Mo

    1

    Team

    Ivan Gergel, MD, MBA

    Ivan Gergel, MD, MBA

    Chief Medical Officer & Managing Partner

    Nayan Gregory Parekh, PhD

    Nayan Gregory Parekh, PhD

    Founder & Managing Partner

    Subhanu Saxena, MBA

    Subhanu Saxena, MBA

    Managing Partner

    Akhil Akula

    Akhil Akula

    Principal

    Jonathan Soll

    Jonathan Soll

    Vice President

    Russell Keathley, PhD

    Russell Keathley, PhD

    Vice President

    Lauren Exposito

    Lauren Exposito

    Investor Relations Associate

    Chris Ferris

    Chris Ferris

    Head of Investor Relations

    Bill Engels

    Bill Engels

    Chief Finance Officer

    Clarisa Gonsalves

    Clarisa Gonsalves

    Executive Administrative Assistant

    Megan McDermott

    Megan McDermott

    Executive Assistant

    Portfolio Breakdown

    Stage Distribution

    Sector Distribution

    Investment Activity

    DealsAvg Round Size

    Portfolio

    5 investments
    CompanyRoundAmountDate
    Butterfly Medical logoButterfly MedicalSeries C$21MMay 2026
    Corsair Pharma logoCorsair PharmaSeries B$23MSep 2023
    Theranica Bio-Electronics logoTheranica Bio-ElectronicsSeries C$45MAug 2022
    Cerexa logoCerexaSeries B$22M
    AAlveusSeries A$197M

    Top Co-Investors

    Last updated: 9 September 2026